BR112019022676A2 - método de prevenção de trombose de derivação da artéria sistêmica-para-pulmonar - Google Patents

método de prevenção de trombose de derivação da artéria sistêmica-para-pulmonar Download PDF

Info

Publication number
BR112019022676A2
BR112019022676A2 BR112019022676A BR112019022676A BR112019022676A2 BR 112019022676 A2 BR112019022676 A2 BR 112019022676A2 BR 112019022676 A BR112019022676 A BR 112019022676A BR 112019022676 A BR112019022676 A BR 112019022676A BR 112019022676 A2 BR112019022676 A2 BR 112019022676A2
Authority
BR
Brazil
Prior art keywords
systemic
pulmonary artery
artery bypass
preventing thrombosis
thrombosis
Prior art date
Application number
BR112019022676A
Other languages
English (en)
Inventor
G Diacovo Thomas
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of BR112019022676A2 publication Critical patent/BR112019022676A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção refere-se ao uso de cangrelor para o tratamento e/ou prevenção de trombose de derivação em pacientes sofrendo de doenças cardíacas congênitas submetidos à cirurgia de derivação. a invenção refere-se também ao uso de cangrelor para o tratamento e/ou prevenção de trombose de stent em pacientes pediátricos submetidos a implante de stent.
BR112019022676A 2017-06-23 2018-06-22 método de prevenção de trombose de derivação da artéria sistêmica-para-pulmonar BR112019022676A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762524102P 2017-06-23 2017-06-23
PCT/EP2018/066817 WO2018234565A1 (en) 2017-06-23 2018-06-22 METHOD FOR PREVENTING SHUNT THROMBOSIS FROM THE SYSTEMIC-PULMONARY ARTERY

Publications (1)

Publication Number Publication Date
BR112019022676A2 true BR112019022676A2 (pt) 2020-05-19

Family

ID=62842064

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019022676A BR112019022676A2 (pt) 2017-06-23 2018-06-22 método de prevenção de trombose de derivação da artéria sistêmica-para-pulmonar

Country Status (9)

Country Link
US (2) US11260071B2 (pt)
EP (1) EP3641784A1 (pt)
KR (1) KR20200018481A (pt)
CN (1) CN110740736A (pt)
BR (1) BR112019022676A2 (pt)
CA (1) CA3060345A1 (pt)
MA (1) MA49452A (pt)
MX (1) MX2019015448A (pt)
WO (1) WO2018234565A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA028885B1 (ru) * 2009-11-11 2018-01-31 Чиези Фармачеутичи С.П.А. Способы лечения или предотвращения тромбоза стента и инфаркта миокарда (варианты)

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US759316A (en) 1902-12-06 1904-05-10 Walter C Runge Telephone-receiver.
FR2530247B1 (fr) 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
US5196404B1 (en) 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
ATE159950T1 (de) 1993-02-10 1997-11-15 Astra Pharma Prod N-alkyl-2-substituierte atp-analoge
SE9604795D0 (sv) 1996-12-20 1996-12-20 Astra Pharma Prod New pharmaceutical formulation
SE9702680D0 (sv) 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
SE9904377D0 (sv) 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
AU2001267916B2 (en) 2000-07-06 2004-09-09 Daiichi Sankyo Company, Limited Hydropyridine derivative acid addition salts
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US20020123791A1 (en) 2000-12-28 2002-09-05 Harrison William J. Stent design with increased vessel coverage
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
US7758630B2 (en) 2003-04-14 2010-07-20 Tryton Medical, Inc. Helical ostium support for treating vascular bifurcations
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
WO2005087266A1 (en) 2004-03-05 2005-09-22 Vddi Pharmaceuticals Combination therapy for inhibition of platelet aggregation
EP1940399A2 (en) 2005-08-19 2008-07-09 Eli Lilly & Company Use of par-i/par- 4 inhibitors for treating or preventing vascular diseases
DE102006020386A1 (de) 2006-04-28 2007-10-31 Dade Behring Marburg Gmbh Verfahren zur Bestimmung der Thrombozytenfunktion unter Flussbedingungen
WO2008006912A2 (en) 2006-07-14 2008-01-17 Biocompatibles Uk Limited Polymer
DE102006051625A1 (de) 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
EP2591783A1 (en) 2007-04-13 2013-05-15 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor
MX2009011619A (es) 2007-04-27 2010-01-18 Cydex Pharmaceuticals Inc Formulaciones que contienen clopidogrel y eter sulfoalquilico-ciclodextrina y metodos de uso.
AU2008247483A1 (en) 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. Intravenous and oral dosing of a direct-acting and reversible P2Y12 inhibitor
US20090043380A1 (en) 2007-08-09 2009-02-12 Specialized Vascular Technologies, Inc. Coatings for promoting endothelization of medical devices
US8998978B2 (en) 2007-09-28 2015-04-07 Abbott Cardiovascular Systems Inc. Stent formed from bioerodible metal-bioceramic composite
WO2009070624A1 (en) 2007-11-27 2009-06-04 The Trustees Of The University Of Pennsylvania Vascular stent
CA2623449C (en) 2008-03-27 2010-11-02 Lance Baldo A novel use of bivalirudin in the treatment of acute coronary syndrome
WO2009140092A1 (en) * 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) * 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US8680052B1 (en) 2013-03-09 2014-03-25 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
KR101138294B1 (ko) 2008-09-24 2012-04-25 김형일 혈관벽 임시 골격용 생분해성 블랜드
WO2011041217A1 (en) 2009-10-02 2011-04-07 Schering Corporation The use of a par-1 antagonist in combination with a p2y12adp receptor antagonist for inhibition of thrombosis
EA028885B1 (ru) 2009-11-11 2018-01-31 Чиези Фармачеутичи С.П.А. Способы лечения или предотвращения тромбоза стента и инфаркта миокарда (варианты)
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20130040898A1 (en) 2010-04-29 2013-02-14 Pär Johansson Methods of treatment of patients at increased risk of development of ischemic events and compounds hereof
CN103582480B (zh) 2011-02-09 2016-03-16 医药公司 治疗肺高压的方法
CN103860459A (zh) 2012-12-11 2014-06-18 天津市汉康医药生物技术有限公司 一种坎格雷洛注射剂及其制备方法
WO2014143107A1 (en) * 2013-03-09 2014-09-18 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
TW201613581A (en) 2014-09-02 2016-04-16 Daiichi Sankyo Co Ltd Pharmaceutical composition for suppression of thromboembolization after stent placement
US9295687B1 (en) 2015-01-14 2016-03-29 The Medicines Company Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same

Also Published As

Publication number Publication date
RU2019142647A (ru) 2021-07-23
WO2018234565A1 (en) 2018-12-27
US20220117994A1 (en) 2022-04-21
KR20200018481A (ko) 2020-02-19
MA49452A (fr) 2021-05-05
US20200054662A1 (en) 2020-02-20
MX2019015448A (es) 2020-02-19
CA3060345A1 (en) 2018-12-27
US11260071B2 (en) 2022-03-01
EP3641784A1 (en) 2020-04-29
RU2019142647A3 (pt) 2021-11-29
CN110740736A (zh) 2020-01-31

Similar Documents

Publication Publication Date Title
WO2018022664A8 (en) Neuromodulating compositions and related therapeutic methods for the treatment of inflammatory and autoimmune diseases
BR112018015897A2 (pt) composições e métodos para procedimentos de cuidados com a pele invasivos e não invasivos
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
Labropoulos et al. Compression stockings to prevent post-thrombotic syndrome
EP3844777A4 (en) MEDICAL DEVICE AND METHODS FOR DIAGNOSIS AND TREATMENT OF DISEASES
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
BR112014003078A2 (pt) dispositivos e métodos para aproximar perfil de secção transversal da vasculatura tendo ramificações
Umehara et al. Hepatic venous outflow obstruction in living donor liver transplantation: balloon angioplasty or stent placement?
MX2021006884A (es) Compuestos y su uso para el tratamiento de la deficiencia de alfa1-antitripsina.
EP4138694A4 (en) METHODS AND SYSTEMS FOR THE TREATMENT OF VENOUS DISEASES
IL287856A (en) Systems and methods for laser eye surgeries and therapeutic treatments
MX2017001682A (es) Composiciones de alergenos alimentarios.
CO2022010592A2 (es) Métodos de tratamiento de la esplenomegalia
MX2021009051A (es) Tratamiento de lesiones cutaneas y prurito en pacientes con prurigo nodular.
BR112019024538A2 (pt) composição para uso no tratamento de rosácea e método para tratar rosácea para um paciente
BR112019022676A2 (pt) método de prevenção de trombose de derivação da artéria sistêmica-para-pulmonar
MX2020013100A (es) Metodos de uso de cd24 para la prevencion y tratamiento de enfermedad de injerto contra hospedero y mucositis.
BR112018014762A2 (pt) método de tratamento da doença de alzheimer (da) precoce
BR112022015533A2 (pt) Composições e métodos para tratar doenças oculares
ZA202007317B (en) Methods of treating patients at risk for renal injury and renal failure
So et al. Effect of compression bandaging on wound healing and psychosocial outcomes in older people with venous ulcers: a randomized controlled trial
ZA202109986B (en) Treatment of heart failure in human subjects
WO2019055776A3 (en) Compositions and methods for treatment of diseases involving cxcl1 function
EP3737381A4 (en) MEDICAL DEVICE AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF AN EYE DISEASE OR DISEASE
BR112022003918A2 (pt) Rebamipida para uso na prevenção e tratamento da doença de crohn

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]